Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 4, 2022, primarily to report its financial and operating results for the fourth quarter and full year ended December 31, 2021. The press release, furnished as Exhibit 99.1, contains the company's performance data. Investors should refer to this press release for detailed financial metrics, including revenue, earnings, and operational updates. While the 8-K itself is a notification of the release, the substance of the investor update lies within the provided press release. This filing serves as the official communication channel for the company's latest performance figures, impacting investor sentiment and future strategic outlook.
Key Highlights
- 1Company announced its financial and operating results for the fourth quarter and full year ended December 31, 2021.
- 2The results were disclosed via a press release furnished with the 8-K filing.
- 3This filing serves as the official notification of Regeneron's latest financial performance.
- 4Investors are directed to the press release (Exhibit 99.1) for detailed financial and operational information.
- 5Information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes.
- 6Includes the Cover Page Interactive Data File in XBRL format.